High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.
[BACKGROUND] The prognostic value of programmed death ligand-1 (PD-L1) expression in patients with gastric or gastroesophageal junction cancer (G/GEJC) at different stages remains unclear.
- HR 1.624
- 연구 설계 cohort study
APA
Zhang HM, Li FP, et al. (2026). High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.. World journal of gastroenterology, 32(8), 115333. https://doi.org/10.3748/wjg.v32.i8.115333
MLA
Zhang HM, et al.. "High PD-L1 expression as a negative prognostic factor in stage III but not in stage II gastric cancer.." World journal of gastroenterology, vol. 32, no. 8, 2026, pp. 115333.
PMID
41809879
Abstract
[BACKGROUND] The prognostic value of programmed death ligand-1 (PD-L1) expression in patients with gastric or gastroesophageal junction cancer (G/GEJC) at different stages remains unclear. We hypothesized that high PD-L1 expression is associated with poor survival in patients with pathological stage III (pIII) G/GEJC.
[AIM] To investigate the relation between PD-L1 expression and survival outcomes in patients with pathological stage II (pII)-pIII G/GEJC.
[METHODS] In this retrospective cohort study, we collected the clinicopathological data of 388 consecutive patients with pII/pIII G/GEJC who underwent gastrectomy without neoadjuvant therapy at Nanfang Hospital, Southern Medical University. Postoperative tissue samples were collected to evaluate PD-L1 expression. Combined positive score (CPS) ≥ 1 was defined as PD-L1-positive, and CPS ≥ 5 as high PD-L1 expression. Survival outcomes were analyzed using Kaplan-Meier and Cox proportional hazards models.
[RESULTS] In pII G/GEJC, no significant differences were found in 3-year disease-free survival (DFS; 88.5% 87.9%, = 0.939) or 3-year overall survival (OS; 92.3% 89.9%, = 0.621) between PD-L1-positive and PD-L1-negative groups or between high and low PD-L1 expression groups (3-year DFS: 91.8% 84.2%, = 0.138; 3-year OS: 94.2% 88.4%, = 0.233). In pIII G/GEJC, PD-L1-positive patients had poorer 3-year DFS (52.2% 67.8%, = 0.030) and 3-year OS (65.1% 78.2%, = 0.007) than PD-L1-negative patients. High PD-L1 expression was associated with significantly inferior 3-year DFS (50.2% 64.8%, = 0.023) and 3-year OS (64.0% 75.1%, = 0.036) compared to low PD-L1 expression. Multivariate analysis revealed that high PD-L1 expression was independently associated with shorter DFS (HR = 1.624, = 0.027) and OS (HR = 1.653, = 0.043) in patients with pIII G/GEJC. Sensitivity analyses confirmed the robustness of the OS findings.
[CONCLUSION] High PD-L1 expression serves as an independent adverse prognostic biomarker in stage III but not stage II G/GEJC. These findings indicate a stage-dependent prognostic value of PD-L1 expression in G/GEJC.
[AIM] To investigate the relation between PD-L1 expression and survival outcomes in patients with pathological stage II (pII)-pIII G/GEJC.
[METHODS] In this retrospective cohort study, we collected the clinicopathological data of 388 consecutive patients with pII/pIII G/GEJC who underwent gastrectomy without neoadjuvant therapy at Nanfang Hospital, Southern Medical University. Postoperative tissue samples were collected to evaluate PD-L1 expression. Combined positive score (CPS) ≥ 1 was defined as PD-L1-positive, and CPS ≥ 5 as high PD-L1 expression. Survival outcomes were analyzed using Kaplan-Meier and Cox proportional hazards models.
[RESULTS] In pII G/GEJC, no significant differences were found in 3-year disease-free survival (DFS; 88.5% 87.9%, = 0.939) or 3-year overall survival (OS; 92.3% 89.9%, = 0.621) between PD-L1-positive and PD-L1-negative groups or between high and low PD-L1 expression groups (3-year DFS: 91.8% 84.2%, = 0.138; 3-year OS: 94.2% 88.4%, = 0.233). In pIII G/GEJC, PD-L1-positive patients had poorer 3-year DFS (52.2% 67.8%, = 0.030) and 3-year OS (65.1% 78.2%, = 0.007) than PD-L1-negative patients. High PD-L1 expression was associated with significantly inferior 3-year DFS (50.2% 64.8%, = 0.023) and 3-year OS (64.0% 75.1%, = 0.036) compared to low PD-L1 expression. Multivariate analysis revealed that high PD-L1 expression was independently associated with shorter DFS (HR = 1.624, = 0.027) and OS (HR = 1.653, = 0.043) in patients with pIII G/GEJC. Sensitivity analyses confirmed the robustness of the OS findings.
[CONCLUSION] High PD-L1 expression serves as an independent adverse prognostic biomarker in stage III but not stage II G/GEJC. These findings indicate a stage-dependent prognostic value of PD-L1 expression in G/GEJC.
MeSH Terms
Humans; Stomach Neoplasms; B7-H1 Antigen; Female; Male; Middle Aged; Retrospective Studies; Neoplasm Staging; Prognosis; Gastrectomy; Biomarkers, Tumor; Aged; Esophagogastric Junction; Kaplan-Meier Estimate; Disease-Free Survival; Adult; Esophageal Neoplasms
같은 제1저자의 인용 많은 논문 (5)
- Anatomical structure of the buccal fat pad and its clinical adaptations.
- [Mechanism of vitamin K2 in modulating matrix Gla protein to inhibit tumor growth in inflammation-associated colorectal cancer model mice].
- GGCT Inhibits Ferroptosis in PTC Cells by Upregulating p53 Through RPS15A.
- Advancing prognostic precision in gastric cancer with an immunoinflammatory index.
- Interaction of MRPL9 and GGCT Promotes Cell Proliferation and Migration by Activating the MAPK/ERK Pathway in Papillary Thyroid Cancer.